Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Total Equity
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Equity
¥12.3B
|
CAGR 3-Years
40%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Equity
¥24.2B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Equity
¥13.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Equity
¥6.8B
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Equity
¥7.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Equity
¥2.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View
In the bustling corridors of Beijing's biotechnology landscape, Beijing Wantai Biological Pharmacy Enterprise Co Ltd has emerged as a significant player, weaving a narrative of innovation and growth. Founded in 1991, Wantai has dedicated itself to the research, development, production, and marketing of in vitro diagnostic tests and vaccines. The company's strategic focus on infectious disease diagnostics has positioned it as a crucial contributor to public health efforts globally. With its widespread product portfolio covering respiratory diseases, sexually transmitted infections, and enteric pathogens, the firm's offerings are integral for medical professionals who rely on Wantai's reliable and precise diagnostic tools to make critical healthcare decisions. Wantai's success isn't merely confined to market presence. The company prides itself on a robust pipeline of vaccine development, targeting diseases neglected by the mainstream pharmaceutical industry. Notably, it gained significant attention during the COVID-19 pandemic for developing diagnostic tests that became pivotal in many countries' strategies to manage and track the virus. The firm's revenue streams are diversified across both domestic and international sales, bolstered by strategic partnerships and collaborations with global health organizations. By remaining at the frontier of scientific advancement and healthcare needs, Wantai thrives not just through innovation but also through its commitment to solving some of the world's most pressing health challenges.
See Also
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Equity?
Total Equity
12.3B
CNY
Based on the financial report for Dec 31, 2024, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Equity amounts to 12.3B CNY.
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
51%
Over the last year, the Total Equity growth was -3%. The average annual Total Equity growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been 40% over the past three years , 51% over the past five years .
You don't have any saved screeners yet